Neurocrine Biosciences PEG Ratio

Neurocrine Biosciences (NBIX) currently reports a PEG ratio of 60.43. That is above the Healthcare sector average of 3.22. Use the charts on this page to explore Neurocrine Biosciences's PEG ratio history and peer comparisons.

Neurocrine Biosciences's PEG ratio of 60.43 is higher than the Healthcare sector average of 3.22. That is roughly 1775.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Neurocrine Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At 60.43, NBIX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 60.43, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 3.22. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On PEG ratio, it currently shows 60.43 versus a sector average near 3.22. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.